UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

Journal of medical economics, 2023, Vol.26 (1), p.1019-1031

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma

Journal of medical economics, 2024, Vol.27 (1), p.738-745

2024

Link zum Volltext

Verfügbarkeit prüfen

Auditing the prescription drug consumer price index in a changing marketplace

Health economics, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefit Manager Discount Programs: The "GoodRx" Model

Value in health, 2024-01, Vol.27 (1), p.35-42

2024

Link zum Volltext

Verfügbarkeit prüfen

Patient Access to Medicines for Rare Diseases in European Countries

Value in health, 2018-05, Vol.21 (5), p.553-560

2018

Link zum Volltext

Verfügbarkeit prüfen

Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US

PharmacoEconomics, 2020-10, Vol.38 (10), p.1115-1121

2020

Link zum Volltext

Verfügbarkeit prüfen

Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018

Value in health, 2020-09, Vol.23 (9), p.1137-1141

2020

Link zum Volltext

Verfügbarkeit prüfen

Opioid Prescribing in United States Health Systems, 2015 to 2019

Value in health, 2021-09, Vol.24 (9), p.1279-1284

2021

Link zum Volltext

Verfügbarkeit prüfen

Does health technology assessment compromise access to pharmaceuticals?

The European journal of health economics, 2023-04, Vol.24 (3), p.437-451

2023

Link zum Volltext

Verfügbarkeit prüfen

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK

The European journal of health economics, 2023-08, Vol.24 (6), p.895-907

2023

Link zum Volltext

Verfügbarkeit prüfen

Does health technology assessment compromise access to pharmaceuticals?

The European journal of health economics, 2023-09, Vol.24 (7), p.1245-1248

2023

Link zum Volltext

Verfügbarkeit prüfen

Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin

PharmacoEconomics, 2021-03, Vol.39 (3), p.317-330

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis

Journal of medical economics, 2024, Vol.27 (1), p.671-677

2024

Link zum Volltext

Verfügbarkeit prüfen

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

Journal of medical economics, 2024, Vol.27 (1), p.219-37

2024

Link zum Volltext

Verfügbarkeit prüfen

What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France

Applied health economics and health policy, 2023-09, Vol.21 (5), p.799-811

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation

Journal of medical economics, 2022-12, Vol.25 (1), p.940-953

2022

Link zum Volltext

Verfügbarkeit prüfen

Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators

Journal of medical economics, 2022-12, Vol.25 (1), p.1118-1126

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Journal of medical economics, 2020-11, Vol.23 (11), p.1311-1320

2020

Link zum Volltext

Verfügbarkeit prüfen

Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database

Journal of medical economics, 2020-11, Vol.23 (11), p.1356-1364

2020

Link zum Volltext

Verfügbarkeit prüfen

Does NICE influence the adoption and uptake of generics in the UK?

The European journal of health economics, 2021-03, Vol.22 (2), p.229-242

2021

Link zum Volltext

Verfügbarkeit prüfen

A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico

PharmacoEconomics - open, 2023-09, Vol.7 (5), p.841-849

2023

Link zum Volltext

Verfügbarkeit prüfen

High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?

PharmacoEconomics - open, 2021-09, Vol.5 (3), p.385-396

2021

Link zum Volltext

Verfügbarkeit prüfen

Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries

The European journal of health economics, 2020-06, Vol.21 (4), p.621-634

2020

Link zum Volltext

Verfügbarkeit prüfen

Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population

PharmacoEconomics - open, 2020-12, Vol.4 (4), p.687-696

2020

Link zum Volltext

Verfügbarkeit prüfen

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

Journal of medical economics, 2018-05, Vol.21 (5), p.1-496

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 112

Suche als RSS-Feed

Aktive Filter

ThemaBusiness & Economics

ThemaHealth Care Sciences & Services

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(111)
Buchkapitel
(1)

Sprache

Englisch
(112)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Economics
(112)
Health Policy & Services
(112)
Life Sciences & Biomedicine
(112)
Social Sciences
(112)
Medicine
(63)
Medicine & Public Health
(62)
Pharmacoeconomics And Health Outcomes
(59)
Health Economics
(57)
Public Health
(53)
Humans
(48)
Health Administration
(41)
Quality Of Life Research
(38)
Pharmacology & Pharmacy
(34)
Original Research Article
(30)
Patients
(29)
Chemicals, Rubber, Drugs, Biotechnology, Plastics
(25)
Cost Analysis
(24)

12 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma

Auditing the prescription drug consumer price index in a changing marketplace

Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefit Manager Discount Programs: The "GoodRx" Model

Patient Access to Medicines for Rare Diseases in European Countries

Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US

Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018

Opioid Prescribing in United States Health Systems, 2015 to 2019

Does health technology assessment compromise access to pharmaceuticals?

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK

Does health technology assessment compromise access to pharmaceuticals?

Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin

Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France

Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation

Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database

Does NICE influence the adoption and uptake of generics in the UK?

A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico

High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?

Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries

Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

Aktive Filter

Suchergebnisse filtern